Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

Summary

Bone marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions using medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study in treating 18 recipients with ischemic limb diseases.

Timeline

Start

2015-05-01

Primary completion

2018-04-27

Completion

2018-12-20

Drugs

Indications